Affinity Asset Advisors LLC Invests $195,000 in Genelux Co. (NASDAQ:GNLX)

Affinity Asset Advisors LLC acquired a new stake in shares of Genelux Co. (NASDAQ:GNLX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 100,000 shares of the company’s stock, valued at approximately $195,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of GNLX. Woodward Diversified Capital LLC boosted its position in Genelux by 2,326.2% during the 4th quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock worth $15,163,000 after buying an additional 1,037,663 shares during the period. Highbridge Capital Management LLC acquired a new position in shares of Genelux during the second quarter worth $1,231,000. Miracle Mile Advisors LLC bought a new stake in shares of Genelux in the 2nd quarter valued at about $58,000. Cubist Systematic Strategies LLC bought a new stake in Genelux in the second quarter valued at approximately $56,000. Finally, Clarity Capital Partners LLC acquired a new stake in Genelux during the 4th quarter valued at approximately $364,000. Institutional investors own 37.33% of the company’s stock.

Insider Transactions at Genelux

In other Genelux news, major shareholder Aladar Szalay sold 33,080 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $2.57, for a total transaction of $85,015.60. Following the completion of the sale, the insider now directly owns 599,821 shares of the company’s stock, valued at approximately $1,541,539.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 331,062 shares of company stock valued at $736,831 over the last three months. Corporate insiders own 9.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GNLX. Benchmark dropped their price target on shares of Genelux from $30.00 to $25.00 and set a “speculative buy” rating on the stock in a research report on Friday, May 31st. Roth Mkm initiated coverage on shares of Genelux in a research report on Tuesday, August 27th. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of Genelux in a research report on Thursday, August 15th. Finally, Roth Capital upgraded Genelux to a “strong-buy” rating in a research report on Tuesday, August 27th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Genelux presently has an average rating of “Buy” and an average price target of $22.33.

Genelux Price Performance

GNLX stock opened at $2.18 on Wednesday. The company’s 50-day moving average is $2.20 and its 200-day moving average is $3.16. Genelux Co. has a 1 year low of $1.60 and a 1 year high of $28.36.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, equities analysts predict that Genelux Co. will post -0.9 EPS for the current fiscal year.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.